Efficiency and safety of total plasma exchange in critically ill cirrhotic patients with acute on chronic liver failure: A pilot study.

ACLF Acute on chronic liver failure Artificial liver support Plasma exchange

Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 21 02 2023
revised: 26 08 2023
accepted: 08 09 2023
pubmed: 16 9 2023
medline: 16 9 2023
entrez: 15 9 2023
Statut: ppublish

Résumé

Treatment of patients with acute on chronic liver failure (ACLF) admitted to the ICU is very limited. The aim of this pilot study was to evaluate the efficiency on liver function and safety of therapeutic plasma exchange (TPE) in critically ill cirrhotic patients admitted with ACLF in a liver ICU. This is a prospective cohort of patients with ACLF grade > 2 treated by TPE admitted to the ICU that was matched to a control group. TPE was performed using a plasma filter (TPE2000, BAXTER®) on a CRRT machine (Prismaflex®, Baxter®). Ratio and type of fluid replacement were 50 % with 5 % albumin solution followed by 50 % with fresh frozen plasma. Seven patients with a mean age of 50.6 ± 7.8 years (all males) and 14 controls matched to age, sex, etiology and cause of decompensation were recruited. At ICU admission, mean MELD score was 39.1 ± 2.7, mean SOFA score was 11.6 ± 5.2 and mean CLIF SOFA score was 12.9 ± 2.6. The grade of ACLF was 3 for 3 patients (42.9 %) and 2 for 4 patients (57.1 %). The TPE group had significantly higher levels of bilirubin (392.3 ± 117.1μmol/l vs. 219 ± 185μmol/l , p = 0.04), and INR values (5.7 ± 3.4 vs. 3.5 ± 0.9, p < 0.005) compared to the control group. Patient survival was respectively 28.6 % and 14.3 % at 30 and 90 days in the TPE group and 35.7 % and 7.14 % in the control group respectively (HR: 1 (95 % CI 0.19- 5.2; p = 1). One patient in the TPE group had a liver transplantation 13 days after admission to ICU and is still alive and none in the control group. Two (28.6 %) patients died from complications related to the double lumen catheter used for TPE. This pilot study of TPE in patients with ACLF grade 2 and 3 showed a marked but transient improvement in liver function tests. TPE worth to be evaluated in large trials in ACLF patients, with a liver transplant project, and less organ failure.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Treatment of patients with acute on chronic liver failure (ACLF) admitted to the ICU is very limited. The aim of this pilot study was to evaluate the efficiency on liver function and safety of therapeutic plasma exchange (TPE) in critically ill cirrhotic patients admitted with ACLF in a liver ICU.
METHODS METHODS
This is a prospective cohort of patients with ACLF grade > 2 treated by TPE admitted to the ICU that was matched to a control group. TPE was performed using a plasma filter (TPE2000, BAXTER®) on a CRRT machine (Prismaflex®, Baxter®). Ratio and type of fluid replacement were 50 % with 5 % albumin solution followed by 50 % with fresh frozen plasma.
RESULTS RESULTS
Seven patients with a mean age of 50.6 ± 7.8 years (all males) and 14 controls matched to age, sex, etiology and cause of decompensation were recruited. At ICU admission, mean MELD score was 39.1 ± 2.7, mean SOFA score was 11.6 ± 5.2 and mean CLIF SOFA score was 12.9 ± 2.6. The grade of ACLF was 3 for 3 patients (42.9 %) and 2 for 4 patients (57.1 %). The TPE group had significantly higher levels of bilirubin (392.3 ± 117.1μmol/l vs. 219 ± 185μmol/l , p = 0.04), and INR values (5.7 ± 3.4 vs. 3.5 ± 0.9, p < 0.005) compared to the control group. Patient survival was respectively 28.6 % and 14.3 % at 30 and 90 days in the TPE group and 35.7 % and 7.14 % in the control group respectively (HR: 1 (95 % CI 0.19- 5.2; p = 1). One patient in the TPE group had a liver transplantation 13 days after admission to ICU and is still alive and none in the control group. Two (28.6 %) patients died from complications related to the double lumen catheter used for TPE.
CONCLUSION CONCLUSIONS
This pilot study of TPE in patients with ACLF grade 2 and 3 showed a marked but transient improvement in liver function tests. TPE worth to be evaluated in large trials in ACLF patients, with a liver transplant project, and less organ failure.

Identifiants

pubmed: 37714512
pii: S2210-7401(23)00131-6
doi: 10.1016/j.clinre.2023.102206
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102206

Informations de copyright

Copyright © 2023 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors whose names are listed certify that they have NO conflicts of interest to declare related to this manuscript.

Auteurs

Ilias Kounis (I)

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, France; Inserm, Université Paris-Saclay, UMR-S 1193, France; Inserm, Physiopathogénèse et Traitement des Maladies du Foie, Université Paris-Saclay, France; FHU Hepatinov, Villejuif 94805, France.

Sophie Caroline Sacleux (SC)

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, France; Inserm, Université Paris-Saclay, UMR-S 1193, France; Inserm, Physiopathogénèse et Traitement des Maladies du Foie, Université Paris-Saclay, France; FHU Hepatinov, Villejuif 94805, France.

Marie Amelie Ordan (MA)

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, France; Inserm, Université Paris-Saclay, UMR-S 1193, France; Inserm, Physiopathogénèse et Traitement des Maladies du Foie, Université Paris-Saclay, France.

Stéphane André (S)

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, France.

Marc Boudon (M)

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, France; Inserm, Université Paris-Saclay, UMR-S 1193, France; Inserm, Physiopathogénèse et Traitement des Maladies du Foie, Université Paris-Saclay, France.

Audrey Coilly (A)

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, France; Inserm, Université Paris-Saclay, UMR-S 1193, France; Inserm, Physiopathogénèse et Traitement des Maladies du Foie, Université Paris-Saclay, France; FHU Hepatinov, Villejuif 94805, France.

Rodolphe Sobesky (R)

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, France; Inserm, Université Paris-Saclay, UMR-S 1193, France; Inserm, Physiopathogénèse et Traitement des Maladies du Foie, Université Paris-Saclay, France; FHU Hepatinov, Villejuif 94805, France.

Eleonora De Martin (E)

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, France; Inserm, Université Paris-Saclay, UMR-S 1193, France; Inserm, Physiopathogénèse et Traitement des Maladies du Foie, Université Paris-Saclay, France; FHU Hepatinov, Villejuif 94805, France.

Didier Samuel (D)

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, France; Inserm, Université Paris-Saclay, UMR-S 1193, France; Inserm, Physiopathogénèse et Traitement des Maladies du Foie, Université Paris-Saclay, France; FHU Hepatinov, Villejuif 94805, France.

Philippe Ichaï (P)

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, France; Inserm, Université Paris-Saclay, UMR-S 1193, France; Inserm, Physiopathogénèse et Traitement des Maladies du Foie, Université Paris-Saclay, France; FHU Hepatinov, Villejuif 94805, France.

Faouzi Saliba (F)

AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, France; Inserm, Université Paris-Saclay, UMR-S 1193, France; Inserm, Physiopathogénèse et Traitement des Maladies du Foie, Université Paris-Saclay, France; FHU Hepatinov, Villejuif 94805, France. Electronic address: faouzi.saliba@aphp.fr.

Classifications MeSH